Can Lifestyle Changes Inform New Human-Rights Based Approaches to Dementia Management, Treatment and Care?

Research Stream: Social Lives

Authors: Maria Gialama, PhD scholar and Graduate Teaching Assistant at Maynooth University’s Department of Psychology, Joanne McVeigh, Assistant Professor of Psychology, Maynooth University, Mac MacLachlan, Professor of Psychology & Social Inclusion, and Co-Director of the ALL Institute, Maynooth University and Georgios Hadjigeorgiou, Professor of Neurology, Medical School, University of Cyprus.

Dementia is an extremely common, progressive neurodegenerative condition which affects almost 55 million people worldwide. Every year, almost 10 million new cases are reported (WHO, 2024). Today, dementia is the seventh leading cause of death and a major cause of disability and dependency among the elderly. Unsurprisingly, the World Health Organization (WHO, 2019), declared dementia a public health priority, not only because of its global prevalence, but also due to its significant impact on families and health service providers. In Ireland, there are 55,000 ‘people living with dementia’ (PwD) and almost 60,000 people who provide care for someone diagnosed with the condition. Long before COVID-19, dementia emerged as a pandemic due to ageing populations and the relationship between age and the incidence of the condition (Fox & Petersen, 2013).

Continue reading “Can Lifestyle Changes Inform New Human-Rights Based Approaches to Dementia Management, Treatment and Care?”

Competition Law Enforcement in the EU and Access to Health Technologies: An Overview of the EU 2024 Competition Law Report on Pharmaceuticals and Medical Technologies – Update on Competition Enforcement in the Pharmaceutical Sector (2018-2022)

Author: Dr. Opeyemi Kolawole Post-doctoral Researcher, PatentsInHumans Project, ALL Insittute and Department of Law and Crimonology

Research Stream: Social Technologies

Competition law is pivotal in maintaining market equilibrium and safeguarding consumer welfare. In the European Union, competition law principles are enshrined in Articles 101 and 102 of the Treaty on the Functioning of the European Union (TFEU). While Article 101 prohibits the formation and enforcement of agreements that have the object or effect of distorting competition, Article 102 prevents a dominant firm from abusing its dominant market position.

Competition in healthcare services is critical to providing access to affordable medicines and medical technologies, ensuring expensive pharmaceutical and medical technologies do not significantly strain public and private finances. With their proactive enforcement of competition rules, the EU Commission and the 27 National Competition Authorities (NCAs) have been instrumental in this regard. In the recent Report on Competition Enforcement in the Pharmaceutical Sector, published in January 2024, the EU Commission provides an overview of how EU competition rules have been enforced to prevent and rectify business practices which may harm competition in the common market and consumer welfare. This article examines some of the key decisions reached by the Commission and some of the NCAs and highlights potential improvement opportunities to maximise consumer welfare.

Continue reading “Competition Law Enforcement in the EU and Access to Health Technologies: An Overview of the EU 2024 Competition Law Report on Pharmaceuticals and Medical Technologies – Update on Competition Enforcement in the Pharmaceutical Sector (2018-2022)”
Skip to content